Your browser doesn't support javascript.
loading
Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica.
Liew, David F L; Mackie, Sarah L; Tison, Alice; Sattui, Sebastian E; Yates, Max; Buchanan, Russell R C; Owen, Claire E.
Affiliation
  • Liew DFL; Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg VIC 3084, Australia; Department of Medicine, University of Melbourne, Parkville, Victoria 3052, Australia. Electronic address: david.liew@au
  • Mackie SL; Division of Rheumatic and Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Worsley Building, Leeds, West Yorkshire LS2 9NL, England.
  • Tison A; LBAI UMR1227, Univ Brest, Inserm, Brest, France; Department of Rheumatology, CHU Brest, France Boulevard TANGUY PRIGENT, Brest, Brittany 29609, France.
  • Sattui SE; Division of Rheumatology and Clinical Immunology, University of Pittsburgh, BST S723, 3500 Terrace Street, Pittsburgh, PA 15261, USA.
  • Yates M; Norwich Medical School, University of East Anglia, Norwich, UK; Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, UK.
  • Buchanan RRC; Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Medicine, University of Melbourne, Parkville, Victoria 3052, Australia.
  • Owen CE; Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Medicine, University of Melbourne, Parkville, Victoria 3052, Australia.
Rheum Dis Clin North Am ; 50(2): 255-267, 2024 May.
Article in En | MEDLINE | ID: mdl-38670724
ABSTRACT
Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMRs) represent a novel, distinct entity, despite many clinical, laboratory, and imaging similarities to classical PMR. Important questions remain in differentiating ICI-PMR from classical PMR, as well as other immune-related adverse events and PMR mimics. Despite this, ICI-PMR currently takes treatment cues from classical PMR, albeit with considerations relevant to cancer immunotherapy. Comparisons between ICI-PMR and classical PMR may provide further bidirectional insights, especially given that important questions remain unanswered about both diseases. The cause of classical PMR remains poorly understood, and ICI-PMR may represent a model of induced PMR, with important therapeutic implications.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polymyalgia Rheumatica / Immune Checkpoint Inhibitors Limits: Humans Language: En Journal: Rheum Dis Clin North Am Journal subject: REUMATOLOGIA Year: 2024 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polymyalgia Rheumatica / Immune Checkpoint Inhibitors Limits: Humans Language: En Journal: Rheum Dis Clin North Am Journal subject: REUMATOLOGIA Year: 2024 Document type: Article